Traded as NYSE: AXON Key people Vivek Ramaswamy (CEO) Headquarters Bermuda Founded 2015 | Industry Biopharmaceutical Website axovant.com Founder Vivek Ramaswamy Parent organization Roivant Sciences Ltd. | |
Stock price AXON (NYSE) US$ 13.00 -0.14 (-1.07%)3 Mar, 12:37 PM GMT-5 - Disclaimer CEO Vivek Ramaswamy (Mar 2015–) Profiles | ||
Axovant sciences ceo biggest biotech ipo ever mad money cnbc
Axovant Sciences, Ltd. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders. The Hamilton, Bermuda-based company has offices in Basel, Switzerland and New York City and is traded on the New York Stock Exchange.
Contents
History
Axovant was founded by Vivek Ramaswamy, who also serves as the company's CEO. Ramaswamy founded Roivant Sciences in May 2014, and created Axovant as a subsidiary of Roivant in October of that year. Axovant's initial public offering in 2015 was the highest grossing IPO in the biotechnology industry to date.
Pipeline
The company's most advanced drug candidate is intepirdine, a potential add-on treatment to donepezil for patients with Alzheimer's disease and patients with dementia with Lewy bodies. Axovant acquired this molecule (previously known as SB-742457) from GlaxoSmithKline in December 2014. Intepirdine is currently being evaluated in a Phase 3 clinical study for patients with mild to moderate Alzheimer's disease. It is also being tested in an ongoing Phase 2b study for patients with dementia with Lewy Bodies, as well as a Phase 2 study evaluating its effect on gait and balance for patients with dementia.
Axovant is simultaneously developing a second compound, nelotanserin. Axovant acquired global rights to nelotanserin from Roivant Sciences, which had previously bought those rights from Arena Pharmaceuticals. Axovant has two ongoing Phase 2 clinical trials examining the use of nelotanserin for the treatment of visual hallucinations in subjects with Lewy Body Dementia as well as rapid eye movement sleep behavior disorder in patients with dementia with Lewy bodies.
Axovant is investigating combinations of cholinesterase inhibitors with glycopyrrolate. Cholinesterase inhibitors have known gastrointestinal side-effects. Glycopyrrolate, as a muscarinic receptor antagonist, may reduce the side effects of cholinesterase inhibitors. The company is developing RVT-103, a combination of glycopyrrolate and donepezil, and RVT-104, a combination of glycopyrrolate and high-dose rivastigmine.